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Objectives The aim of this study was to analyze the yet ill-defined relationship of distinct human monocyte subsets with
cardiovascular outcomes in a broad patient population at cardiovascular risk.
Background Monocytes, the most abundant immune cell type found in atherosclerotic plaques, are crucial promoters of
atherogenesis. Three distinct human monocyte subsets exist: classical CD14CD16, intermediate
CD14CD16, and nonclassical CD14CD16 monocytes. Immunomodulation of distinct monocyte sub-
sets has recently been discussed as a new therapeutic avenue in atherosclerosis.
Methods Cardiovascular events in 951 subjects referred for elective coronary angiography were prospectively analyzed.
Monocyte subset analysis was performed using flow cytometry, blinded to patients’ clinical characteristics, and
patients were categorized according to quartiles of total monocyte and monocyte subset counts. The primary
endpoint was defined a priori as the first occurrence of cardiovascular death, acute myocardial infarction, or non-
hemorrhagic stroke. Endpoint adjudication was done blinded to monocyte subset distribution.
Results During a mean follow-up period of 2.6  1.0 years, 93 patients experienced the primary endpoint. In univariate
Kaplan-Meier analysis, counts of total (p  0.010), classical CD14CD16 (p  0.024), and intermediate
CD14CD16 (p  0.001) monocytes predicted the primary endpoint, whereas nonclassical monocytes did
not (p  0.158). After full adjustment for confounders, CD14CD16 monocytes remained the only mono-
cyte subset independently related to cardiovascular events (fourth vs. first quartile: hazard ratio: 3.019; 95%
confidence interval: 1.315 to 6.928; p  0.009).
Conclusions CD14CD16 monocytes independently predicted cardiovascular events in subjects referred for elective coro-
nary angiography. Future studies will be needed to elucidate whether CD14CD16 monocytes may become
a target cell population for new therapeutic strategies in atherosclerosis. (J Am Coll Cardiol 2012;60:
1512–20) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.019Monocytes are the central drivers of vascular inflammation
in atherosclerosis. They contribute to atherogenesis from
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accepted July 17, 2012.the formation of the earliest asymptomatic atherosclerotic
lesions, namely fatty streaks, to final plaque rupture with
potentially fatal outcomes (1,2). Although experimental
studies have proven a causative role of monocytes in athero-
genesis (3), epidemiological analyses have failed to unequiv-
ocally demonstrate an association between circulating
monocyte counts and cardiovascular disease (4).
Importantly, monocytes display substantial heterogeneity,
which is reflected by the differential surface expression of
the lipopolysaccharide receptor (CD14) and the low-affinity
Fc-III receptor (CD16). Although a subset-specific con-
tribution of monocytes has been proposed in recent years on
the basis of laboratory data (3), monocyte heterogeneity has
not been analyzed thoroughly in the context of human
atherosclerosis.
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October 16, 2012:1512–20 CD14CD16 Monocytes and Cardiovascular OutcomesThe existence of 3 distinct monocyte subsets is ac-
knowledged by recent consensus (5), namely, classical
CD14CD16 monocytes, intermediate CD14CD16
monocytes, and nonclassical CD14CD16 mono-
cytes. However, most previous studies did not distinguish
between intermediate CD14CD16 and nonclassical
CD14CD16 monocytes but subsumed these 2 subsets as
D16-positive monocytes. Consequently, the intermediate
onocyte subset was by far the most poorly characterized mono-
yte subset until recently (6). Although numerically the small-
st monocyte subpopulation and seemingly displaying just
n intermediate immunophenotype, CD14CD16
onocytes are a clearly distinguishable subset, as evidenced
y the distinct gene expression profile recently been reported
y Wong et al. (7) as well as our group (6), independently of
ach other.
We previously reported a predictive role of intermediate
D14CD16 monocyte counts in patients with
hronic kidney disease (CKD) (8), a selected patient group
t highest cardiovascular risk. Of note, CKD-associated
mmune dysfunction, which is characterized by profound
hifts in monocyte subsets (9,10), and the CKD-specific
attern of accelerated atherosclerosis both preclude an
ncritical generalization of our previous findings to the
eneral population.
Against this background, we initiated the HOM
WEET HOMe (Heterogeneity of Monocytes in Subjects
ho Undergo Elective Coronary Angiography—The
omburg Evaluation) study to test the hypothesis that
ounts of intermediate CD14CD16 monocytes pre-
ict cardiovascular events in subjects at cardiovascular risk
eferred for elective coronary angiography.
ethods
etween May 2007 and June 2010, subjects who were
dmitted to Saarland University Medical Center for elective
oronary angiography were invited to participate in the
OM SWEET HOMe study. The study was approved by
he local ethics committee, and all participants provided
ritten informed consent.
At study inclusion, a history of smoking, diabetes, current
rug intake, and cardiovascular comorbidities were recorded
sing a standardized questionnaire. Patient-reported co-
orbidities were confirmed by chart review. Prevalent
ardiovascular disease was diagnosed in subjects with coro-
ary artery disease (a history of myocardial infarction or
oronary artery angioplasty, stent implantation, or bypass
urgery), cerebrovascular disease (a history of major stroke
defined as acute onset of neurological symptoms persisting
or24 h] or carotid endarterectomy or stent implantation)
r peripheral artery disease (a history of nontraumatic lower
xtremity amputation or lower limb artery bypass surgery,
ngioplasty, or stent implantation).
Subjects were categorized as active smokers if they were
urrent smokers or had stopped smoking 1 month beforetudy entry. Subjects with self-
eported or physician-reported
iabetes mellitus, with nonfast-
ng blood glucose levels 200
g/dl, with fasting blood glucose
evels 126 mg/dl, or with cur-
ent use of hypoglycemic medi-
ation were categorized as having diabetes. Body mass index
as calculated as weight in kilograms divided by the square
f height in meters.
Coronary angiography was performed on the day of
ospital admission. Coronary artery disease was defined in
ubjects who had stenoses  50% in a major coronary artery
n current coronary angiography and/or who had a history
f coronary revascularization for coronary artery stenosis.
Because of their potential interference with monocyte
ubset counts, intake of systemic immunosuppressive agents
as considered an exclusion criterion for the present analysis.
aboratory measurements. Blood samples were obtained
nder standardized conditions. Blood levels of creatinine,
otal cholesterol, high-density lipoprotein cholesterol, low-
ensity lipoprotein cholesterol and C-reactive protein
CRP) were measured using standard methods. Estimated
lomerular filtration rate was calculated using the 4-variable
odification of Diet in Renal Disease study equation.
Leukocyte and monocyte counts were measured with
utomated cell counters using standard techniques. Using
ow cytometry, monocyte subpopulations were analyzed in
whole-blood assay using 100 l of whole blood, as
described and validated previously (6). Cells were stained by
monoclonal antibodies (CD86 PE [HA5.2B7; Beckman-
Coulter, Krefeld, Germany], CD16 PeCy7 [3G8; BD
Biosciences, Heidelberg, Germany], CD14 PerCP [M9;
D Biosciences]) and analyzed using flow cytometry
FACSCalibur and FACS Canto II; BD Biosciences) using
ell Quest and FACSDiva software (BD Biosciences).
In brief, monocytes were gated in an SSC/CD86 dot plot,
dentifying monocytes as CD86 cells with monocyte scatter
properties. Subsets of CD14CD16, CD14CD16,
and CD14CD16monocytes were defined according to the
surface expression pattern of the lipopolysaccharide receptor
CD14 and the Fc-III receptor CD16 (compare Fig. 1 for a
representative example). Nomenclature of monocyte subsets fol-
lowed the recommendations of the Nomenclature Committee of
the International Union of Immunological Societies (5).
Outcome analysis. After study inclusion, all study partic-
ipants, or their next of kin, were contacted annually until
death or until September 30, 2011, for outcome analysis.
We obtained medical records from the treating physicians
for verification of all events reported by study participants or
their next of kin. All events were adjudicated by the same
investigators, who were blinded to monocyte data, accord-
ing to the following definitions.
The composite primary endpoint was defined a priori as
the first occurrence of cardiovascular death, acute myocar-
Abbreviations
and Acronyms
CKD  chronic kidney
disease
CRP  C-reactive proteindial infarction, or nonhemorrhagic stroke. Definition of
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CD14CD16 Monocytes and Cardiovascular Outcomes October 16, 2012:1512–20acute myocardial infarction followed the joint European
Society of Cardiology, American College of Cardiology
Foundation, American Heart Association, and World
Heart Federation task force consensus (11). Stroke was
defined as “rapidly developing clinical symptoms and/or
signs of focal (or at times global) disturbance of cerebral
function lasting  24 hours (unless interrupted by surgery)
or leading to death, with no apparent cause other than of
vascular origin,” in accordance with the World Health
Organization (12). Those subjects without evidence of
cerebral hemorrhage on cerebral imaging were defined to
have nonhemorrhagic stroke. Deaths due to cardiovascular
auses included sudden cardiac death, death from acute
yocardial infarction, death from congestive heart fail-
re, fatal stroke, fatal arrhythmia, and other fatal vascular
vents.
As a secondary endpoint, we defined the first occurrence
f any cardiovascular event (defined as myocardial infarc-
ion; coronary artery angioplasty, stent implantation, or
ypass surgery; stroke [with acute onset of neurological
ymptoms persisting for 24 h]; carotid endarterectomy or
stent implantation; nontraumatic lower extremity amputa-
tion; or lower limb artery bypass surgery, angioplasty, or
stent implantation) or death.
Statistical analysis. Data management and statistical anal-
ysis were performed using PASW Statistics 18 (SPSS, Inc.,
Chicago, Illinois) and the software environment for statis-
tical computing R. Two-sided p values 0.05 were consid-
Figure 1 Flow Cytometric Analysis
of Monocyte Subpopulations
Depicted are classical CD14CD16 monocytes, intermediate
CD14CD16 monocytes, and nonclassical CD14CD16 monocytes
(representative example).ered significant. Categorical variables are presented as per-cents of patients and were compared using chi-square tests.
Continuous data are expressed as mean SD (or, in case of
skewed distributions, as median [interquartile range]) and
were compared using Mann-Whitney U tests. The associ-
ations between continuous variables were assessed using
Spearman rank correlation testing.
Subjects were divided into 4 equally sized groups (quar-
tiles) according to their total monocyte counts and mono-
cyte subset counts. Kaplan-Meier survival curves were used
to compare event-free survival (i.e., time until first occur-
rence of the primary or secondary endpoint) between
groups. Participants with noncardiovascular death were
censored at the time of death. The log-rank test was used to
test the hypothesis that at least 1 of the survival curves
differs from the others.
Cox proportional-hazards models were calculated to an-
alyze the relationship of total monocyte and monocyte
subset cell counts with event-free survival after adjustment
for age and sex (model 1); further adjustment for systolic
blood pressure, plasma cholesterol, diabetes, smoking, and
body mass index (model 2); and finally further adjustment
for estimated glomerular filtration rate, CRP, prevalent
cardiovascular disease, and total leukocyte count (model 3).
To assess the predictive discrimination of each Cox
model, we calculated the C-statistic (13), which provides
the proportion of evaluable patient pairs that can be cor-
rectly classified by a model.
Results
Baseline characteristics. Monocyte subset analysis was
intended in 999 HOM SWEET HOMe participants. Of
these, 36 subjects were on systemic immunosuppressive
medication, and 12 did not undergo planned coronary
angiography after admission, leaving 951 subjects in the
present analysis.
Baseline characteristics of these 951 patients are pre-
sented in Table 1. As expected, study participants had a
high burden of risk factors and cardiovascular disease.
Consequently, cardioprotective medication use was highly
prevalent.
Study participants were followed for a mean of 2.6  1.0
ears; 3 patients were lost to follow-up. The predefined
omposite primary endpoint (cardiovascular death, acute
yocardial infarction, or nonhemorrhagic stroke) occurred
n 93 subjects, of whom 29 subjects had nonfatal acute
yocardial infarctions, 24 had nonfatal nonhemorrhagic
trokes, and 45 subjects died of cardiovascular causes. Study
articipants who experienced the primary endpoint were
lder, had more comorbidities, and had higher markers of
ystemic inflammation (Table 1).
onocyte subset counts and cardiovascular risk factors. At
tudy initiation, the mean monocyte count was 583  211
ells/l, of which 470  179 cells were CD14CD16
monocytes, 42  24 cells were CD14CD16 mono-
cytes, and 71  37 cells were CD14CD16 mono-
s
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C
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October 16, 2012:1512–20 CD14CD16 Monocytes and Cardiovascular Outcomescytes. Associations of monocyte (subset) counts with
traditional and nontraditional cardiovascular risk factors
are specified in Table 2. Cell counts of all 3 monocyte
Baseline Characteristics of Study ParticipantsTable 1 Baseline Characteristics of Study Pa
Variable
Total Cohort
(n  951)
Age (yrs) 65.1 10.3
Body mass index (kg/m2) 28.5 4.6
Systolic BP (mm Hg) 147 22
Diastolic BP (mm Hg) 82 11
Hip circumference (cm) 103.5 10.0
Waist circumference (cm) 101.5 12.5
Creatinine (mg/dl) 1.0 0.3
eGFR (ml/min/1.73 m2) 75 20
CRP (mg/l) 1.9 (0.9–4.0)
Total cholesterol (mg/dl) 187 47
LDL cholesterol (mg/dl) 113 41
HDL cholesterol (mg/dl) 49 15
Triglycerides (mg/dl) 129 (93–182)
Leukocytes (1/l) 6,709 1,957
Total monocytes (1/l) 583 211
Women 305 (32.1%)
Smoking 122 (12.8%)
Diabetes mellitus 363 (38.2%)
Prevalent CVD 568 (59.7%)
Prevalent CAD 513 (53.9%)
Cerebrovascular artery disease 94 (9.9%)
Peripheral artery disease 67 (7.0%)
Beta-blockers 710 (74.7%)
ACE inhibitors 559 (58.8%)
Angiotensin receptor blockers 193 (20.3%)
Calcium-channel blockers 191 (20.1%)
Antiplatelet agents (%) 714 (75.1%)
Statins (%) 562 (59.1%)
Values are mean  SD, median (interquartile range), or n (%).
ACE angiotensin-converting enzyme; BP blood pressure; CAD co
eGFR  estimated glomerular filtration rate; HDL  high-density lipopr
Correlation Coefficients of Monocyte (Subset) Counts With TraditioTable 2 Correlation Coefficients of Monocyte (Subset) Counts
Variable
Total Monocytes
CD14
Mono
r p Value r
Age 0.019 0.564 0.048
Body mass index 0.047 0.150 0.011
Systolic BP 0.006 0.853 0.019
Diastolic BP 0.042 0.196 0.055
Hip circumference 0.064 0.054 0.024
Waist circumference 0.122 0.001 0.086
Creatinine 0.084 0.010 0.058
eGFR 0.020 0.537 0.012
CRP 0.213 0.001 0.192
Total cholesterol 0.048 0.136 0.051
LDL cholesterol 0.024 0.461 0.025
HDL cholesterol 0.150 0.001 0.148
Triglycerides 0.078 0.016 0.057
Leukocytes 0.629 0.001 0.632Abbreviations as in Table 1.ubsets were correlated with traditional markers of in-
ammation (CRP and leukocyte counts). Additionally,
D14CD16 and CD14CD16 monocyte
ants
rimary EndPoint
(n  858)
Primary Endpoint
(n  93) p Value
64.7 10.3 68.8 9.1 0.001
28.4 4.6 29.0 5.0 0.396
147 22 150 23 0.547
82 10 81 11 0.192
03.4 9.7 104.2 12.3 0.990
01.1 12.1 105.6 15.0 0.039
1.0 0.3 1.1 0.5 0.001
76 19 69 22 0.001
1.9 (0.9–3.8) 3.7 (1.6–6.4) 0.001
187 47 181 42 0.184
114 41 111 37 0.561
49 15 48 13 0.032
29 (92–182) 124 (96–182) 0.866
,640 1,931 7,344 2,094 0.001
577 211 633 209 0.005
83 (33.0%) 22 (23.7%) 0.079
13 (13.2%) 9 (9.7%) 0.415
12 (36.4%) 51 (54.8%) 0.001
96 (57.8%) 72 (77.4%) 0.001
49 (52.3%) 64 (68.8%) 0.003
72 (8.4%) 22 (23.7%) 0.001
52 (6.1%) 15 (16.1%) 0.002
39 (74.5%) 71 (76.3%) 0.906
94 (57.6%) 65 (69.9%) 0.067
69 (19.7%) 24 (25.8%) 0.372
69 (19.7%) 22 (23.7%) 0.653
45 (75.2%) 69 (74.2%) 0.912
01 (58.4%) 61 (65.6%) 0.399
artery disease; CRP C-reactive protein; CVD cardiovascular disease;
DL  low-density lipoprotein.
nd Nontraditional Cardiovascular Risk FactorsTraditional and Nontraditional Cardiovascular Risk Factors
 CD14CD16
Monocytes
CD14CD16
Monocytes
Value r p Value r p Value
0.138 0.066 0.040 0.100 0.002
0.728 0.064 0.049 0.164 0.001
0.563 0.044 0.174 0.137 0.001
0.091 0.013 0.682 0.057 0.078
0.461 0.104 0.002 0.185 0.001
0.010 0.128 0.001 0.206 0.001
0.075 0.152 0.001 0.099 0.002
0.709 0.145 0.001 0.089 0.006
0.001 0.233 0.001 0.102 0.002
0.116 0.045 0.163 0.007 0.838
0.451 0.019 0.554 0.007 0.819
0.001 0.131 0.001 0.052 0.112
0.077 0.069 0.035 0.104 0.001
0.001 0.443 0.001 0.242 0.001rticip
No P
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CD14CD16 Monocytes and Cardiovascular Outcomes October 16, 2012:1512–20counts showed weak, albeit significant, correlations with
body mass index, renal dysfunction, age, and serum
triglycerides.
Total monocyte and CD14CD16– monocyte counts
were higher in men than in women. In patients with
diabetes, all monocyte subset counts were elevated (Online
Table S1). Interestingly, prevalent cardiovascular disease
was not associated with a shift in monocyte (subset) counts.
Further associations between monocyte (subset) counts and
intake of cardioprotective medication are listed in Online
Table S1.
Total monocyte counts, monocyte subset counts, and
cardiovascular outcomes. Patients who experienced events
had a mean of 508 178 CD14CD16monocytes/l,
47  22 CD14CD16 monocytes/l, and 77  43
CD14CD16 monocytes/l. In contrast, patients who
had uneventful follow-up had a mean of 466  178
CD14CD16 monocytes/l (p  0.011 compared
with patients with events), 41  24 CD14CD16
monocytes/l (p  0.001), and 70  37 CD14CD16
monocytes/l (p  0.105).
After stratifying the study cohort by monocyte (subset)
cell counts into quartiles, higher counts of total monocytes
(log-rank test, p  0.010), CD14CD16 monocytes
(p  0.024), and CD14CD16 monocytes (p 
0.001), but not of CD14CD16 monocytes (p 
0.158), were univariately associated with the primary end-
point of cardiovascular death, acute myocardial infarction,
or nonhemorrhagic stroke in Kaplan-Meier survival analysis
(Fig. 2, Online Figs. S1A to S1C).
Similarly, higher CD14CD16 monocyte counts
Figure 2 Relationship Between Quartiles of CD14CD16
Monocyte Counts and Event-Free Survival
Primary endpoint: cardiovascular death, acute myocardial infarction,
or nonhemorrhagic stroke; Kaplan-Meier analysis with log-rank test.significantly predicted the occurrence of any cardiovascularevent, pre-defined as a secondary endpoint, in Kaplan-
Meier analysis (p  0.028) (Fig. 3), whereas counts of total
monocytes (p 0.098), CD14CD16monocytes (p
0.066), and CD14CD16 monocytes (p  0.062) only
ended to predict adverse cardiovascular outcomes.
In multivariate regression analysis, subjects with higher
ell counts of CD14CD16 monocytes remained at
igher risk for adverse outcomes after adjustment for age
nd sex (model 1); further adjustment for systolic blood
ressure, plasma cholesterol, smoking, diabetes mellitus,
nd body mass index (model 2); and additional adjustment
or renal function, CRP, prevalent cardiovascular disease,
nd total leukocyte counts (model 3), compared with indi-
iduals with the lowest counts of CD14CD16 mono-
ytes (quartile 1) (Table 3).
In contrast to CD14CD16 cells, neither total
onocyte counts nor counts of CD14CD16 – or
D14CD16 monocytes predicted adverse outcomes
n fully adjusted models (Table 3).
In addition, Table 4 provides the C-statistics correspond-
ng to the Cox analyses reported in Table 3. Discrimination
verall improved for covariate adjustment. Regardless of
djustment, a specific benefit in terms of prediction perfor-
ance was seen for CD14CD16 monocytes. Thus,
he C-statistic analysis supports our conclusion that only
D14CD16 monocyte measurements improve risk
rediction over the total monocyte count. To further illus-
rate that CD14CD16 monocytes might render
rognostic information for cardiovascular outcome in
ddition to more conventional markers of inflammation,
e cross-stratified the study cohort by the median of
D14CD16 monocyte counts and CRP higher than
Figure 3 Relationship Between Quartiles of CD14CD16
Monocyte Counts and Event-Free Survival
Secondary endpoint: cardiovascular event; Kaplan-Meier analysis with log-rank test.
total leu
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October 16, 2012:1512–20 CD14CD16 Monocytes and Cardiovascular Outcomesand lower than 2 mg/l, which corresponds to the CRP
inclusion criterion of Justification for the Use of Statins in
Prevention: An Intervention Trial Evaluating Rosuvastatin
(14). Those subjects who had CD14CD16 monocyte
counts higher than the median in conjunction with higher
CRP levels had the worst outcomes (Online Fig. S1D) in
Kaplan-Meier analysis (p  0.001).
Discussion
The identification of a subset-specific involvement of mono-
cytes in murine models of atherosclerosis was a breakthrough
in cardiovascular research (15,16). Lately, specific immuno-
modulation of a distinct monocyte subset has been discussed as
a promising therapeutic avenue in atherosclerosis (17). This
notion is backed by the successful application of cell-targeted
therapy in other fields of medicine, such as the introduction of
rituximab in patients with lymphoma (18).
Unfortunately, advances in understanding of murine ath-
erosclerosis are not paralleled by a better grasp of human
pathology, given that the potential monocyte target subpop-
Adjusted Cox Regression Analysis (Different Models) for CardiovasTable 3 Adjusted Cox Regression Analysis (Different Models) f
Monocyte Subset n
Events
(n)
Model 1
HR 95% CI
Total monocytes
Quartile 1 242 17 1.000
Quartile 2 235 19 1.263 (0.656–2.432)
Quartile 3 236 24 1.528 (0.820–2.848)
Quartile 4 238 33 2.308 (1.280–4.162)
CD14CD16 monocytes
Quartile 1 238 18 1.000
Quartile 2 238 21 1.186 (0.631–2.229)
Quartile 3 237 21 1.261 (0.671–2.369)
Quartile 4 238 33 2.144 (1.198–3.836)
CD14CD16 monocytes
Quartile 1 238 9 1.000
Quartile 2 238 28 3.191 (1.505–6.766)
Quartile 3 237 23 2.74 (1.267–5.926)
Quartile 4 238 33 3.899 (1.861–8.168)
CD14CD16 monocytes
Quartile 1 238 21 1.000
Quartile 2 238 18 0.796 (0.424–1.495)
Quartile 3 237 25 1.225 (0.685–2.190)
Quartile 4 238 29 1.348 (0.767–2.372)
Model 1 includesmonocyte (subset) counts, age, and sex; model 2 is further adjusted for systolic blo
for estimated glomerular filtration rate, C-reactive protein, prevalent cardiovascular disease, and
CI  confidence interval; HR  hazard ratio.
C-Statistics Corresponding to theox Regre sion Analyses Reported in Table 3Table 4 -Statistics Correspondi g to theCox Regression Analyses Reported in Table 3
Monocyte Subset Model 1 Model 2 Model 3
Total monocytes 0.666 0.705 0.734
CD14CD16 monocytes 0.661 0.701 0.732
CD14CD16 monocytes 0.699 0.723 0.748CD14CD16 monocytes 0.666 0.698 0.731ulation in atherosclerosis has not been convincingly identi-
fied yet. So far, most information derives from few cross-
sectional studies: in a heterogenous cohort of 308 subjects,
a shift toward CD16-positive monocytes was associated
with the presence of coronary artery disease (19). Later,
small cross-sectional studies linked high counts of CD16-
positive monocytes with the presence of vulnerable athero-
sclerotic plaques in patients with stable angina pectoris (20)
and with fibrous cap thickness in patients with unstable
angina pectoris (21). Of note, none of these studies distin-
guished intermediate CD14CD16 monocytes from
nonclassical CD14CD16 monocytes (as discussed in
detail previously [22,23]). Consequently, so far, the respec-
tive roles of CD14CD16 and CD14CD16
monocytes in human atherosclerosis have not been fully
discerned. Against this background, large prospective stud-
ies of monocyte subsets and cardiovascular outcomes have
been demanded recently (17).
We previously set out to analyze the relationship between
subset-specific monocyte counts and adverse cardiovascular
outcomes in selected patient groups. Initially, we focused
our analysis on patients with CKD receiving dialysis treat-
ment (10,24,25), reasoning that this highest cardiovascular
risk group would allow us to gather information in a limited
sample size because of the high event rate. This allowed us
to demonstrate CD14CD16 monocytes to be inde-
pendent predictors of cardiovascular events in dialysis pa-
tients (10). However, a drawback of this approach was the
Eventsrdiovascular Events
Model 2 Model 3
e HR 95% CI
p
Value HR 95% CI
p
Value
1.000 1.000
5 1.228 (0.636–2.368) 0.541 1.009 (0.515–1.976) 0.979
2 1.487 (0.796–2.779) 0.213 1.229 (0.644–2.348) 0.532
5 2.180 (1.195–3.977) 0.011 1.381 (0.681–2.801) 0.371
1.000 1.000
7 1.182 (0.627–2.227) 0.605 1.051 (0.551–2.006) 0.880
1 1.251 (0.665–2.352) 0.487 1.036 (0.540–1.988) 0.915
0 2.039 (1.124–3.701) 0.019 1.259 (0.625–2.536) 0.520
1.000 1.000
2 3.121 (1.470–6.629) 0.003 3.218 (1.459–7.095) 0.004
0 2.508 (1.154–5.454) 0.02 2.444 (1.074–5.563) 0.033
1 3.722 (1.770–7.829) 0.001 3.019 (1.315–6.928) 0.009
1.000 1.000
9 0.793 (0.421–1.494) 0.473 0.867 (0.456–1.649) 0.663
4 1.193 (0.661–2.156) 0.558 1.138 (0.622–2.082) 0.675
0 1.251 (0.705–2.220) 0.444 1.037 (0.571–1.883) 0.906
sure, plasma cholesterol, diabetes, smoking, and bodymass index; andmodel 3 is further adjusted
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ing a translation of these results to non-CKD populations.
Next we prospectively analyzed monocyte heterogeneity
in subjects with earlier stages of CKD not requiring dialysis.
At baseline, these patients had CD14CD16 cell counts
between those of subjects with preserved renal function and
those of patients with CKD receiving dialysis. Nonetheless,
higher CD14CD16 monocyte counts again predicted
cardiovascular outcomes in these patients (8).
To test the validity of these findings in a broad patient
group not affected by the CKD-associated monocyte subset
shift, we recruited subjects from the general population at
cardiovascular risk, who were referred for elective coronary
angiography. Our HOM SWEET HOMe study, the larg-
est prospective cohort study on monocyte heterogeneity so
far, thereby comprised a representative sample of subjects at
cardiovascular risk with either prevalent coronary artery
disease or a high burden of risk factors. At baseline, cell
counts of all 3 monocyte subsets were correlated with
traditional as well as nontraditional cardiovascular risk
factors. Interestingly, CD14CD16 monocytes seem
particularly to integrate cardiovascular risk burden, a notion
that is supported by earlier data (26). Of most interest,
CD14CD16 monocytes were the only independent
redictors of adverse cardiovascular outcomes after full
djustment for traditional and nontraditional cardiovascular
isk factors in the HOM SWEET HOMe study.
With regard to our fully adjusted Cox regression analysis,
ne might suspect a threshold effect of CD14CD16
onocyte counts, because in this model, quartiles 2 to 4
redicted adverse outcomes to a similar extent. A compa-
able conclusion could be also drawn from our previous
tudy on CD14CD16 monocytes and survival in
on-dialysis-dependent patients with CKD; here, the
aplan-Meier curve of the second tertile clearly separated
rom the first tertile but ran close and parallel to the third
ertile (8).
However, this concept is merely a hypothesis originating
posteriori from the present dataset. Future studies with
redefined cell count cutoff values should therefore prospec-
ively test this idea.
Circumstantial evidence suggesting a role of CD16-
ositive monocytes in atherosclerosis supports our present
ndings. Mechanistically, the significance of CD16-positive
onocytes in atherosclerosis is emphasized by their proin-
ammatory capacity (6,27) along with their endothelial
ffinity (28). Their preferential adherence to activated en-
othelial cells (29) together with their potential to secrete
nterleukin-6, matrix metalloproteinase-9, and chemokine
C-C motif) ligand 2 and to attract T-lymphocytes and
urther monocytes (30) should be considered proatheroscle-
otic features.
Furthermore, the role of CD16-positive monocytes in
therosclerotic vascular disease is underscored by their
ssociation with subclinical atherosclerosis (31). wOf note, among CD16-positive monocytes, intermediate
D14CD16 monocytes can be viewed as particularly
proatherogenic, as they selectively express C-C chemokine
receptor type 5 (6,8,29), which has been associated with
atherosclerosis in experimental (1) and large epidemiologi-
cal (32–34) studies. Moreover, subset-specific high reactive
oxygen species production and CD74 expression predispose
CD14CD16 monocytes to propagate atherogenesis
(6). These proatherogenic virtues are further extended by the
proangiogenic capacity of intermediate CD14CD16
monocytes (6,35), linking them to potential plaque neovas-
cularization as an important component in advanced stages
of atherosclerosis (36).
Our study has several strengths that support the signifi-
cance of CD14CD16 monocytes in cardiovascular
disease.
First, the large cohort size provides firm ground for our
results. Second, our monocyte analysis protocol, which
has been validated (6) against a suggested reference
method (37), reliably distinguishes between intermediate
CD14CD16 and nonclassical CD14CD16
monocytes (6). Third, analysis of monocyte subsets was
performed blinded to baseline characteristics, and endpoints
were adjudicated blinded to the distribution of monocyte
subpopulations.
As the major limitation, our study cannot prove causality,
because of its nature as a cohort study.
However, our study provides an extensive dataset on
human monocyte heterogeneity in atherosclerosis, a field in
which a plethora of murine data on monocyte heterogeneity
contrast with the paucity of human data. Considering the
limitations of murine models (1,2,38), clinical studies have
been demanded to fill this knowledge gap (17).
One might argue that our present findings are in contra-
diction to results from murine studies that favor a proath-
erosclerotic role of Ly6Chigh monocytes, conventionally
egarded as counterpart of human CD14CD16
onocytes, over Ly6Clow monocytes, which are convention-
lly viewed as homologues of both human CD14CD16
nd CD14CD16 monocytes (39).
However, this concept has recently been refined by Cros
t al. (40), who reported that human CD14CD16– and
D14CD16 monocytes both cluster together with
urine Ly6Chigh monocytes, whereas CD14CD16
monocytes cluster together with Ly6Clow monocytes. This
nding is of great importance, because it could help recon-
ile murine studies with our present findings as well as with
revious human studies that favored CD16-positive mono-
ytes in cardiovascular disease.
In addition, 2 aspects deserve special consideration when
nterpreting results from murine studies. First, most murine
tudies on monocyte heterogeneity in atherosclerosis ana-
yzed only 2 murine monocyte subsets: Ly6Chigh and
Ly6Clow cells (16). Second, many murine studies are per-
formed in apolipoprotein E/ mice on an atherogenic diet,hich accordingly show massively elevated cholesterol levels
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
1519JACC Vol. 60, No. 16, 2012 Rogacev et al.
October 16, 2012:1512–20 CD14CD16 Monocytes and Cardiovascular Outcomesand a very profound rise of Ly6Chigh cells (up to 14-fold in
individual studies [15]) without concomitant changes in
Ly6Clow monocyte counts (15). In humans, such extreme
alterations are restricted to rare disease states such as
familial hypercholesterolemia, in which a significant in-
crease of CD14CD16 monocytes has been reported
(41). In contrast, wild-type mice on an atherogenic diet
display significant increases neither of Ly6Chigh nor of
Ly6Clow cell counts and no atherosclerotic lesions despite
persisting hypercholesterolemia (15). Accordingly, in a pre-
vious study in healthy volunteers, we did not observe
associations between CD14CD16 monocytes and
cholesterol levels or subclinical atherosclerosis (31).
Taken together, we believe that our present results do
not conflict with findings from earlier murine studies, if
critical attention is paid to the respective experimental
setting.
Ideally, studies on monocyte heterogeneity in other ex-
perimental animals, such as pigs, whose immune system is
evolutionary closer to that of humans and which show a
comparable monocyte subset distribution (42), will comple-
ment our existing knowledge in the future.
Conclusions
We report an association of CD14CD16 monocytes
with cardiovascular events in subjects from the general
population referred for elective coronary angiography. It
remains to be proven whether the CD14CD16
monocyte subset represents a target cell population for new
therapeutic strategies in atherosclerosis.
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